Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Summary
Third Opinion Trial Synopsis:
This study wants to find out if using isatuximab with lenalidomide can help treat high-risk multiple myeloma after a stem cell transplant.
This study wants to find out if using isatuximab with lenalidomide can help treat high-risk multiple myeloma after a stem cell transplant.
*Third Opinion AI Generated Synopsis
Trial Summary
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: